首页> 外文OA文献 >PCV68 Pharmacogenomic Testing for Warfarin Use in Typical outpatient Settings Lowers Health Care Costs: The Medco-Mayo Warfarin Effectiveness Study

【2h】

PCV68 Pharmacogenomic Testing for Warfarin Use in Typical outpatient Settings Lowers Health Care Costs: The Medco-Mayo Warfarin Effectiveness Study

机译：在典型的门诊病人中使用PCV68药物基因组学检测华法林可降低医疗保健成本：Medco-Mayo华法林有效性研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Aubert R.E.; Epstein R.S.; Yao J.; OKane D.J.; Tinnirello J.; Teagarden J.R.; Moyer T.P.;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. HEALTH CARE COSTS AMONG PATIENTS DIAGNOSED WITH DEEP VEIN THROMBOSIS IN THE OUTPATIENT SETTING AND TREATED WITH RIVAROXABAN VERSUS LOW-MOLECULAR-WEIGHT HEPARIN AND WARFARIN [J] . Deitelzweig S., Laliberte F., Raut R., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第3期

机译：诊断为深静脉血栓形成的患者在门诊就诊的健康费用及利伐沙班与低分子肝素和华法林治疗
2. COST-EFFECTIVENESS OF RIVAROXABAN VERSUS WARFARIN FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION IN THE GUANGDONG HEALTHCARE SETTING IN CHINA [J] . Zhou J., Huang B. Y., Yang M. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：利伐沙班与华法林预防中国广东省非瓣膜性心房纤颤卒中的成本效益
3. Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting [J] . Joris Kleintjens, Xiao Li, Steven Simoens, PharmacoEconomics . 2013,第10期

机译：在比利时的医疗机构中，利伐沙班与华法林对预防心房颤动的成本效益
4. Controlling Healthcare Costs By Reengineering A Hospital's Outpatient Services Area [C] . Brian L.McGuire, Mehmet C.Kocakulah Annual meeting of the Decision Sciences Institute . 1997

机译：通过重新设计医院的门诊服务区来控制医疗费用
5. Cost-Effectiveness of Current Anticoagulation Care versus Genetic Testing of CYP2C9 and VKORC1 Prior to Long-Term Warfarin Anticoagulation Care: The Implementation of Discrete Event Simulation Model on the Natural History of Venous Thromboembolism. [D] . Teschemaker, Anna R. 2011

机译：当前抗凝治疗的成本效果与长期华法林抗凝治疗之前的CYP2C9和VKORC1遗传检测的关系：基于静脉血栓栓塞自然史的离散事件模拟模型的实现。
6. Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting [O] . Joris Kleintjens, Xiao Li, Steven Simoens, -1

机译：在比利时的医疗机构中利伐沙班与华法林对预防心房颤动的成本效益
7. Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin and Aspirin for Stroke Prevention Atrial Fibrillation (SPAF) in the Indonesian healthcare setting [O] . Iwan Dwiprahasto, Erna Kristin, Dwi Endarti, 2019

机译：罗昔芬林与华法林和阿司匹林对印度尼西亚医疗环境中卒中预防心房颤动（SPAF）相比的成本效力分析

PCV68 Pharmacogenomic Testing for Warfarin Use in Typical outpatient Settings Lowers Health Care Costs: The Medco-Mayo Warfarin Effectiveness Study

著录项

引文网络

相似文献

相关主题

期刊订阅